Свойства и применение дерматологического индекса оценки качества жизни у пациентов с псориазом

Введение. По итогам клинических исследований в мире накоплен значительный опыт применения дерматологического индекса качества жизни (ДИКЖ). Он может оказаться полезным при предоставлении медицинской помощи пациентам с псориазом в повседневной клинической практике.
Целью исследования явился систематический анализ исключительно новых результатов (за последние 5 лет) применения ДИКЖ для оценки тяжести течения псориаза.
Материалы и методы. Развернутый поиск релевантных источников осуществлялся с использованием библиографической базы PubMed/Medline. В поисковой строке применялись ключевые слова Dermatology Life Quality Index, Psoriasis. Исключались работы, основная цель которых не касалась проблем применения ДИКЖ, а также однотипные публикации, описывающие повторяющиеся свойства и характеристики ДИКЖ.
Результаты. ДИКЖ может применяться в рамках клинических исследований, а также при анализе данных в условиях реальной клинической практики. В ряде исследований ДИКЖ применяется для анализа результативности новых видов терапии. Его показатели обычно коррелируют с данными оценки по индексу площади и тяжести псориатических поражений (PASI) и результатами применения других шкал оценки качества жизни. Большая часть научных публикаций посвящена применению ДИКЖ в рамках клинических исследований, в том числе анализу эффективности биологической терапии.
Обсуждение. Чтобы получить все доказательства целесообразности применения ДИКЖ и его модификаций в различных клинических ситуациях, можно расширить использование комплексного подхода, основанного на одновременной комбинации различных шкал в пилотных исследованиях.

1. Rencz F, Szabó Á, Brodszky V. Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review. Value Heal. 2021;24(8):1158-1171. doi:https://doi.org/10.1016/j.jval.2021.02.006

2. Ali FM, Cueva AC, Vyas J, et al. A systematic review of the use of quality of life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577-593. doi:10.1111/bjd.14788

3. Basra MKA, Chowdhury MMU, Smith E V., Freemantle N, Piguet V. A Review of the Use of the Dermatology Life Quality Index as a Criterion in Clinical Guidelines and Health Technology Assessments in Psoriasis and Chronic Hand Eczema. Dermatol Clin. 2012;30(2):237-244. doi:10.1016/j.det.2011.11.002

4. Eissing L, Rustenbach SJ, Krensel M, et al. Psoriasis registries worldwide: systematic overview on registry publications. J Eur Acad Dermatology Venereol. 2016;30(7):1100-1106. doi:10.1111/jdv.13634

5. FINLAY AY, KHAN GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x

6. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol. 2017;31(2):205-212. doi:10.1111/jdv.13854

7. Dave R, Alkeswani A. An Overview of Biologics for Psoriasis. J Drugs Dermatology. 2021;20(11):1246-1247. doi:10.36849/JDD.6040

8. Chen Y, Wei L, Song Y, et al. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study. Ann Med. 2023;55(1). doi:10.1080/07853890.2023.2231847

9. Houghton K, Patil D, Gomez B, Feldman SR. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. Dermatol Ther (Heidelb). 2021;11(4):1373-1384. doi:10.1007/s13555-021-00564-2

10. Barbieri JS, Gelfand JM. Influence of “Not Relevant” Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. JAMA Dermatology. 2019;155(6):743. doi:10.1001/jamadermatol.2018.5655

11. Rencz F, Brodszky V, Gulácsi L, et al. Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2019;33(7):e267-e269. doi:10.1111/jdv.15537

12. Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123-127. doi:10.1111/jdv.15226

13. Rencz F, Gulácsi L, Péntek M, et al. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. Br J Dermatol. 2018;179(5):1102-1108. doi:10.1111/bjd.16927

14. Nasreen S, Ahmed I, Effendi S. Frequency and magnitude of anxiety and depression in patients with psoriasis vulgaris. J Coll Physicians Surg Pak. 2008;18(7):397-400.

15. Tadros A, Vergou T, Stratigos AJ, et al. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatology Venereol. 2011;25(11):1282-1287. doi:10.1111/j.1468-3083.2010.03965.x

16. Khan JM, Rathore MU, Tahir M, Abbasi T. Dermatology Life Quality Index In Patients Of Psoriasis And Its Correlation With Severity Of Disease. J Ayub Med Coll Abbottabad. 2020;32(1):64-67. http://www.ncbi.nlm.nih.gov/pubmed/32468758

17. Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatology Venereol. 2017;31(2):213-220. doi:10.1111/jdv.14007

18. Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatology Venereol. 2021;35(2):431-440. doi:10.1111/jdv.16632

19. Blauvelt A, Wu J, Armstrong A, Menter A, Liu C, Jacobson A. Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. J Drugs Dermatology. 2020;19(5):487-492. doi:10.36849/JDD.2020.4957

20. Prevezas C, Katoulis AC, Papadavid E, Panagakis P, Rigopoulos D. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis. Ski appendage Disord. 2019;5(6):344-349. doi:10.1159/000499348

21. Leong WC, Tang JJ. Scalp psoriasis and Dermatology Life Quality Index: A retrospective study based on 12-year data from the Malaysian Psoriasis Registry. Malaysian Fam physician Off J Acad Fam Physicians Malaysia. 2022;17(3):84-88. doi:10.51866/oa.146

22. Liluashvili S, Kituashvili T. Dermatology Life Quality Index and disease coping strategies in psoriasis patients. Adv Dermatology Allergol. 2019;36(4):419-424. doi:10.5114/ada.2018.75810

23. Davison NJ, Thompson AJ, Turner AJ, et al. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. Value Heal. 2018;21(8):1010-1018. doi:10.1016/j.jval.2017.10.024

24. Imafuku S, Kanai Y, Murotani K, et al. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study. J Dermatol Sci. 2021;101(3):185-193. doi:10.1016/j.jdermsci.2021.01.002

25. Robinson S, Moon TM, Eng TK, et al. Dermatology Life Quality Index in Patients with Psoriasis Treated with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study. Drugs - real world outcomes. 2023;10(2):291-298. doi:10.1007/s40801-023-00359-1

26. Takahashi H, Iinuma S, Tsuji H, Honma M, Iizuka H. Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol. 2014;41(8):686-689. doi:10.1111/1346-8138.12544

27. Norris D, Photiou L, Tacey M, et al. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat. 2017;28(8):731-736. doi:10.1080/09546634.2017.1329501

28. Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatol Ther (Heidelb). 2021;11(4):1265-1275. doi:10.1007/s13555-021-00545-5

29. Armstrong AW, Reich K, Foley P, et al. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Am J Clin Dermatol. 2019;20(1):155-164. doi:10.1007/s40257-018-0396-z

30. Li N, Teeple A, Muser E, Lucas J, Hetherington J, Fitzgerald T. Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data. Clin Exp Dermatol. 2020;45(5):572-575. doi:10.1111/ced.14142

31. Puig L, Zhu B, Burge R, et al. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Longterm Clinical Study. J Clin Aesthet Dermatol. 2020;13(10):18-22.

32. Rencz F, Gulácsi L, Péntek M, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol. 2020;182(5):1167-1175. doi:10.1111/bjd.1843533. Rencz F, Mitev AZ, Szabó Á, et al. A Rasch model analysis of two interpretations of “not relevant” responses

33. on the Dermatology Life Quality Index (DLQI). Qual life Res an Int J Qual life Asp Treat care Rehabil. 2021;30(8):2375-2386. doi:10.1007/s11136-021-02803-7

34. Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-337. doi:10.1111/jdv.12106

35. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1

36. Pongparit K, Chularojanamontri L, Limphoka P, Silpa-Archa N, Wongpraparat C. Effectiveness of and factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study. J Dermatol. 2018;45(5):540-545. doi:10.1111/1346-8138.14270

37. Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156-1161. doi:10.1016/j.jaad.2016.07.034

38. Ljosaa T, Stubhaug A, Mork C, Moum T, Wahl A. Improvement in Psoriasis Area and Severity Index Score Predicts Improvement in Skin Pain Over Time in Patients with Psoriasis. Acta Derm Venereol. 2013;93(3):330-334. doi:10.2340/00015555-1456

39. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163-173. doi:10.1016/j.jad.2008.06.026

40. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder. Arch Intern Med. 2006;166(10):1092. doi:10.1001/archinte.166.10.1092

41. Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2009;10(5):531-539. doi:10.1016/j.sleep.2008.06.003

42. Bharmal M, Payne K, Atkinson MJ, Desrosiers M-P, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36. doi:10.1186/1477-7525-7-36